A Phase 4 Open-Label Study to Evaluate Vedolizumab IV Dose Optimization on Treatment Outcomes In Nonresponders With Moderately to Severely Active Ulcerative Colitis (ENTERPRET)
Phase of Trial: Phase IV
Latest Information Update: 11 Jan 2019
At a glance
- Drugs Vedolizumab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Acronyms ENTERPRET
- Sponsors Takeda
- 04 Jun 2018 Planned number of patients changed from 200 to 250.
- 04 Jun 2018 Planned End Date changed from 20 Mar 2020 to 30 Jun 2020.
- 04 Jun 2018 Planned primary completion date changed from 18 Oct 2019 to 26 Jan 2020.